List view / Grid view
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics.
In this interview, Sam Hasson, Senior Director at Rgenta Therapeutics, shares his journey in drug discovery, from graduate school to industry, and his current work developing small molecule therapeutics to target RNA processing. He discusses the challenges and opportunities in the field of RNA-centric drug discovery and highlights the potential…
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
A study out of Austria suggests gene changes in those with biliary tract cancer offers new avenues for new precision oncology therapies.
US study identifies promising new target, in protein remnants from an ancient virus, for treating underlying cause of ALS.
Fresh insights from University of Edinburgh into a protein that causes damage in kidneys and hearts could open up new treatment options for chronic kidney disease.
The drug resistant bacteria: CRAB, came into the ICU in hospitals in Hangzhou, China, creating an urgent need for a thorough understanding of the persistence, transmission, and evolution of CRAB populations in such environments.
This article highlights a new approach to address human genetics, using STING-seq which provides roadmap to identify variants and genes, enabling deeper understanding of the noncoding genome and targets for therapies
Safer and more effective blood thinners could be on the way following a ground-breaking discovery by US researchers, that have designed a new compound to target blood clots.
Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).
US scientists have used mouse models of pancreatic cancer to identify genes used by tumour cells to grow uncontrollably.
US researchers find combination of chloroquine and venetoclax promotes cancer cell death in mouse models with acute myeloid leukaemia (AML).
US study suggest worms could be a good research model for understanding the endocannabinoid system—and possibly developing better drugs.
Tom Darlington, Senior Director at nanoComposix, discusses scaling up manufacturing of nanomaterials for regulated applications and the rewards of working on biomedical projects.
The researchers identified 1,068 transposable element-derived transcripts with the potential to produce tumour antigens that could serve as targets for new immunotherapies.
